c-Myc is required for the CHREBP-dependent activation of glucose-responsive genes.
Glucose regulates programs of gene expression that orchestrate changes in cellular phenotype in several metabolically active tissues. Carbohydrate response element-binding protein (ChREBP) and its binding partner, Mlx, mediate glucose-regulated gene expression by binding to carbohydrate response elements on target genes, such as the prototypical glucose-responsive gene, liver-type pyruvate kinase (Pklr). c-Myc is also required for the glucose response of the Pklr gene, although the relationship between c-Myc and ChREBP has not been defined. Here we describe the molecular events of the glucose-mediated activation of Pklr and determine the effects of decreasing the activity or abundance of c-Myc on this process. Time-course chromatin immunoprecipitation revealed a set of transcription factors [hepatocyte nuclear factor (HNF)1alpha, HNF4alpha, and RNA polymerase II (Pol II)] constitutively resident on the Pklr promoter, with a relative enrichment of acetylated histones 3 and 4 in the same region of the gene. Glucose did not affect HNF1alpha binding or the acetylation of histones H3 or H4. By contrast, glucose promoted the recruitment of ChREBP and c-Myc and increased the occupancy of HNF4alpha and RNA Pol II, which were coincident with the glucose-mediated increase in transcription as determined by a nuclear run-on assay. Depletion of c-Myc activity using a small molecule inhibitor (10058-F4/1RH) abolished the glucose-mediated recruitment of HNF4alpha, ChREBP, and RNA Pol II, without affecting basal gene expression, histone acetylation, and HNF1alpha or basal HNF4alpha occupancy. The activation and recruitment of ChREBP to several glucose-responsive genes were blocked by 1RH, indicating a general necessity for c-Myc in this process.
Zhang
Pili
P
Department of Medicine, Division of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA.
Metukuri
Mallikarjurna R
MR
Bindom
Sharell M
SM
Prochownik
Edward V
EV
O'Doherty
Robert M
RM
Scott
Donald K
DK
D000818:Animals; D001483:Base Sequence; D051778:Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / Q000378:metabolism*; D001665:Binding Sites; D045744:Cell Line, Tumor; D005947:Glucose / Q000494:pharmacology*; D006801:Humans; D007515:Islets of Langerhans / Q000187:drug effects / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008957:Models, Genetic; D008969:Molecular Sequence Data; D009928:Organ Specificity / Q000187:drug effects; D011401:Promoter Regions, Genetic / Q000235:genetics; D011485:Protein Binding / Q000187:drug effects; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism*; D011770:Pyruvate Kinase / Q000235:genetics; D051381:Rats; D013844:Thiazoles / Q000494:pharmacology; D014157:Transcription Factors / Q000378:metabolism; D014158:Transcription, Genetic / Q000187:drug effects; D015533:Transcriptional Activation / Q000187:drug effects*
C524814:5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one; D051778:Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; C499329:Max protein, rat; C442825:Mlxipl protein, rat; D016271:Proto-Oncogene Proteins c-myc; D013844:Thiazoles; D014157:Transcription Factors; D011770:Pyruvate Kinase; D005947:Glucose
J Biol Chem. 2005 Dec 2;280(48):39827-34
16204235
J Biol Chem. 2002 Feb 8;277(6):3829-35
11724780
Diabetes. 1998 Aug;47(8):1231-5
9703322
Cell. 2009 Aug 7;138(3):430-2
19665966
Cell. 2009 Aug 7;138(3):489-501
19665971
J Biol Chem. 2003 Feb 21;278(8):6588-95
12480946
Biochem J. 1999 Jan 1;337 ( Pt 1):1-11
9854017
J Biol Chem. 2002 Sep 6;277(36):32746-52
12087089
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3685-9
8386381
Mol Cell. 2006 Oct 20;24(2):233-43
17052457
Trends Endocrinol Metab. 2005 Dec;16(10):489-94
16269245
Annu Rev Nutr. 2007;27:179-92
17428181
J Biol Chem. 1993 Jun 15;268(17):12787-95
8509413
Biochem Biophys Res Commun. 2008 Jul 18;372(1):131-6
18468514
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9116-21
11470916
Science. 2009 Apr 3;324(5923):92-4
19251593
Nat Rev Cancer. 2008 Dec;8(12):976-90
19029958
Cancer Res. 2007 Jun 1;67(11):5061-3
17545579
Biochem J. 2002 Dec 15;368(Pt 3):931-7
12230428
Diabetes. 2006 May;55(5):1179-89
16644671
Biochem Biophys Res Commun. 2006 Feb 10;340(2):449-56
16375857
Curr Opin Cell Biol. 2008 Jun;20(3):334-40
18513937
Nature. 1996 Dec 5;384(6608):455-8
8945470
Diabetes. 2000 Mar;49(3):424-30
10868964
J Biol Chem. 2000 Apr 28;275(17):12515-20
10777539
Biochem J. 1995 May 15;308 ( Pt 1):105-11
7755551
J Am Chem Soc. 2009 Jun 3;131(21):7390-401
19432426
Diabetes. 2004 Jan;53(1):149-59
14693709
FASEB J. 2003 Sep;17(12):1715-7
12958186
J Biol Chem. 2008 Aug 29;283(35):24029-38
18591247
Am J Physiol Endocrinol Metab. 2007 Jul;293(1):E48-56
17341548
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13710-5
11698644
Curr Opin Genet Dev. 2008 Apr;18(2):130-6
18282700
J Biol Chem. 2001 Mar 23;276(12):9437-45
11112788
Hum Mol Genet. 2001 Mar 15;10(6):617-27
11230181
Cell. 2009 Jul 10;138(1):129-45
19596240
Genes Dev. 2008 Oct 15;22(20):2755-66
18923074
Annu Rev Biochem. 2007;76:75-100
17362198
Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2198-202
8700908
Cancer Res. 2006 Sep 15;66(18):8927-30
16982728
Mol Cell Biol. 1993 Sep;13(9):5216-24
8395000
Cell. 2007 Jul 13;130(1):77-88
17632057
Cell. 2003 Dec 12;115(6):751-63
14675539
Trends Biochem Sci. 2008 Jun;33(6):265-73
18467100
Annu Rev Biochem. 2003;72:449-79
12651739
Mol Cell Biol. 2007 Mar;27(6):2059-73
17242204
Mol Endocrinol. 2004 May;18(5):1051-63
14694084
J Mol Biol. 2009 Sep 25;392(3):578-88
19631660
FASEB J. 2009 Sep;23(9):2855-65
19406844
EMBO J. 2000 Aug 15;19(16):4257-64
10944108
Mol Cancer Ther. 2007 Sep;6(9):2399-408
17876039
J Biol Chem. 1993 Nov 15;268(32):23881-90
8226928
Cancer Res. 2008 Dec 1;68(23):9654-62
19047142
Biotechniques. 2000 Nov;29(5):1012-4, 1016-7
11084863
J Biol Chem. 2006 Sep 29;281(39):28721-30
16885160
Nat Cell Biol. 2006 Jul;8(7):764-70
16767079
Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E788-801
17106062